Drugs / VM-1500
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02489487 | Sep → Oct 2014 | HIV infectious disease | Viriom | Completed | No outcome recorded |
| Phase 1 | NCT02489435 | Jul 2012 → Jun 2013 | HIV infectious disease | Viriom | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02485509 | Mar → Dec 2013 | HIV infectious disease | Viriom | Completed | No outcome recorded |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT02489461 | Aug 2014 → Apr 2016 | HIV infectious disease | Viriom | Completed | Met primary |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2014-03-21 | ChemRar Research and Development Institute, LLC | Компания «Вириом» представила экспертному сообществу результаты международного клинического исследования препарата VM-1500 на конференции CROI-2014 в Бостоне chemrar.ru ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VM-1500 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02485509 ↗ |
| Route | Oral | “multiple oral administration” NCT02489435 ↗ |